In this study, molecular characterization via high-throughput analysis and biochemical assays reveals that NRP1 is highly expressed in AD, which suggests that NRP1 may be a potential genetic therapy target in AD patients with COVID-19. The gene discussed is NRP1; the disease is COVID-19.